Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

According to Benzinga Pro, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically advanced asset ...

Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...

Equities research analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for Exelixis in a ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The biotechnology sector is expanding quickly due to rising demand for ...

Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top ...